The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent ...

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced the presentation of new data from zipalertinib REZILIENT1 and REZILIENT2 trials at the International Association of the Study of ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

US FDA grants fast track designation to DualityBio's next-generation HER3 ADC DB-1310 to treat nonsquamous non-small cell lung cancer: Shanghai Wednesday, July 23, 2025, 14:30 Hrs ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

UCLA Health researchers at the Jonsson Comprehensive Cancer Center have recently won a pair of grants worth in total nearly ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...

By JAMES BROWN Glasgow News 1 Daryl Murphy was always prepared as a coach and school administrator, but he was not ready for ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...